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Abstract
Purpose: To compare the ovarian response predictive ability of anti- Müllerian hor-
mone (AMH), follicle- stimulating hormone (FSH), and estradiol (E2) and to determine 
the age- specific distribution of serum AMH concentrations of Japanese women.
Methods: This was a multicenter (four- site), observational, analytic, cross- sectional 
Japanese study consisting of two parts: Study 1 (the prediction of the ovarian re-
sponse of 236 participants who were undergoing controlled ovarian stimulation [COS]) 
and Study 2 (the distribution of the AMH concentration with an assay of 417 healthy 
women who were aged 20- 49 years and who had normal menstrual cycles).
Results: The AMH had a significantly higher predictive value for the normal and high 
responders than FSH and E2 as a stronger correlation between the ovarian response 
and AMH was observed than for FSH and E2. The serum AMH concentration de-
creased proportionally with age.
Conclusion: The AMH concentration correlated well with the oocyte count in the pa-
tients who were undergoing COS for in vitro fertilization and was shown to predict the 
risk of ovarian hyperstimulation syndrome among these patients.
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1  | INTRODUCTION
Potentially related factors to low fertility in Japan include a decrease 
in marriage rates, delay in marrying, deferring childbearing to later 
years, and improved access to contraception.1 These factors have 
resulted from demographic and socioeconomic changes, as well as 
medical advancements in past decades, which have affected the role 
of women in society. Furthermore, postponing childbearing to the 
biological age limit has resulted in an increase in the need for, and 
seeking of, infertility treatments, including assisted reproductive 
techniques.1-3
Currently, in order to achieve better reproductive outcomes with 
assisted reproductive techniques, such as in vitro fertilization (IVF), con-
trolled ovarian stimulation (COS) is used for the induction of multiple 
follicular development.4 Variations in the ovarian response to hormonal 
stimulation are considerably large; thus, selecting individualized COS 
protocols is of great importance.4,5 Such individualized COS protocols 
can reduce the risk of ovarian hyperstimulation in women that might 
have an excessive response. Additionally, individualized COS protocols 
can lead to improved outcomes in women with a poor ovarian response.6
Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic con-
dition that results from COS. The conditions that are associated with 
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a higher risk of OHSS are a young age, low body weight, polycystic 
ovary syndrome (PCOS), higher doses of exogenous gonadotropins, 
high absolute serum estradiol (E2) levels or a rate of increase in E2, 
and previous episodes of OHSS.7 It is important to predict and pre-
vent OHSS as the associated morbidity can be severe. Furthermore, 
improper management can result in severe sequelae.8 In severe OHSS 
cases, renal failure leads to decreased urine volume, followed by re-
spiratory and circulatory failure. Life- threatening thrombosis also 
can develop with the progression of OHSS. Therefore, the prediction 
of OHSS recently has gained considerable importance among IVF 
specialists.
Previously, anti- Müllerian hormone (AMH) has been identified as 
a predictor of OHSS.5,9,10 Anti- Müllerian hormone is a protein that be-
longs to the transforming growth factor- β family. In men, AMH is se-
creted by the Sertoli cells in the testes during embryogenesis and plays 
a significant role in sexual differentiation, particularly in inhibiting the 
development of the Müllerian ducts.11 In women, AMH is produced 
by the granulosa cells of the pre- antral and small antral follicles during 
the early stages of follicular recruitment. Its production decreases with 
follicular growth.12 With aging, the circulating AMH levels decrease, 
until its production eventually ceases during menopause.13
The serum AMH level indicates the number of pre- antral and 
small antral follicles and it is useful to assess the reserve capacity 
of the ovaries.14,15 The use of AMH levels to predict OHSS leads to 
decreased risks of treatment- related complications, thereby leading 
to safer, more efficient infertility treatment. The efficacy of AMH 
as a measure of ovarian reserve is well known; thus, its use in sev-
eral clinical settings, including infertility treatment, has become 
widespread.10
The distribution of AMH levels in healthy Japanese women has yet 
to be reported. Additionally, assessments of the relationship between 
the retrieved oocyte count and AMH levels are scarce in this popu-
lation. This study aimed to assess AMH as a predictor of the ovarian 
response during COS and to determine the age- specific distribution of 
AMH levels in healthy Japanese women.
2  | MATERIALS AND METHODS
2.1 | Study design and treatment
This was a multicenter (four- site), observational, analytic Japanese 
study consisting of two parts; namely, Study 1 and Study 2. Study 1 was 
a retrospective, cross- sectional study and consisted of the evaluation 
of the ovarian response prediction during COS by using the Elecsys® 
AMH Plus assay (Roche Diagnostics International, Ltd., Rotkreuz, 
Switzerland). This part of the study was conducted at Asada Ladies 
Clinic and IVF Namba Clinic between December, 2014 and March, 
2016. Study 2 was a prospective study and consisted of determining 
the distribution of the AMH concentration levels (measured using the 
Elecsys® AMH Plus assay) of 417 healthy Japanese women. This part 
of the study was conducted at Tokushima University Hospital, Asada 
Ladies Clinic, and Yamaguchi University Hospital between May, 2014 
and May, 2015.
2.2 | Participants
2.2.1 | Study 1
Women who were planning to undergo COS were eligible for the 
study if they were aged between 20 and 45 years, had a >0.8 mL 
serum blood sample available for analysis (taken during a previous 
clinical visit) that was collected within 2- 4 days from the beginning of 
their menstrual period, they were planning to undergo COS by either 
a gonadotropin- releasing hormone (GnRH) antagonist protocol or a 
short or long GnRH agonist protocol, the presence of both ovaries had 
been confirmed by transvaginal echography, and if they had provided 
written informed consent to participate in the study.
The main exclusion criteria were as follows: PCOS; ovarian abnor-
malities (eg, an ovarian cyst sized >2 cm, confirmed by transvaginal 
echography); hydrosalpinx; endometriosis; a history of ovarian surgery 
within 6 months prior to the beginning of the study; metabolic or en-
docrine diseases (diabetes, thyroid disease, Cushing’s syndrome etc.); 
administration of the combined oral contraceptive pill <60 days from 
the beginning of the study; hormone treatment within the last 21 days 
with clomiphene, aromatase inhibitor, gonadotropin (all types), es-
trogen receptor inhibitor, tamoxifen, or a GnRH agonist or GnRH 
antagonist; malignant tumor; patients undergoing radiotherapy or che-
motherapy; drug addiction or alcoholism; patients who had joined the 
clinical study within the last 90 days of the study; patients taking med-
ications for which COS is contraindicated; a positive pregnancy test; 
COS from the clomiphene administration method; and individuals who 
were judged by the investigator as unfit to participate in the study.
2.2.2 | Study 2
The AMH concentration tends to decrease with age and it is meas-
ured before beginning infertility treatment in routine clinical practice. 
Therefore, it was aimed to determine the distribution of the AMH con-
centration in healthy women by age group. For this, a 3 year layer was 
set for women who were aged 30- 44 years and a 5 year layer was set 
for women who were aged 20- 29 years and >45 years, with a total of 
eight layers for the total sample population. The study targeted 50 pa-
tients for each layer, yielding a sample size of 400 (8 × 50) participants.
Women aged between 20 and 49 years, with a normal menstrual 
cycle duration (defined as 25- 38 days, according to the guideline from 
the Japan Society of Obstetrics and Gynecology16), who clearly re-
called the date of their last period, had a body mass index (BMI) rang-
ing between 19 and 30 kg/m2, and whose AMH and other hormone 
levels were measured were eligible for enrollment.
The exclusion criteria were as follows: PCOS; patients with ovarian 
abnormalities; endometriosis; a history of ovarian surgery, diabetes, 
thyroid disease, metabolic, or endocrine disease (eg, adrenal gland 
disease); hormone treatment or the combined oral contraceptive pill 
within 90 days of the beginning of the study); a history of anticancer or 
immunosuppressive drug use; and participants whose concentrations 
of thyroid- stimulating hormone (TSH) and free thyroxine (FT4) were 
outside of the reference range.
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2.3 | Study reagents and assays
During Study 1, the levels of AMH, luteinizing hormone (LH), follicle- 
stimulating hormone (FSH), prolactin, E2, progesterone (P4), testos-
terone, TSH, and FT4 were measured in the serum that had been 
obtained within 2- 4 days after the beginning of the menstrual pe-
riod. The reagents that were used for the measurement of AMH are 
described in detail elsewhere.17 All the other serum markers were 
measured with an electro- chemiluminescence immunoassay on an au-
tomated analyzer (cobas; Roche Diagnostics International, Ltd.). The 
GnRH antagonist protocol or GnRH agonist long or short protocol was 
used for COS. From day 3 of the menstrual period, the patients un-
derwent the administration of 225 IU or 300 IU of FSH and/or human 
menopausal gonadotrophin. The growth of the follicles was monitored 
by the E2, FSH, and LH levels and by an ultrasound examination. The 
dose was adjusted if necessary in order to obtain mature oocytes. The 
presence of the mature follicles was confirmed and oocyte retrieval 
was performed 36 hours after triggering oocyte maturation with 
human chorionic gonadotrophin or with a gonadotrophin- releasing 
hormone agonist.
2.4 | Endpoints
2.4.1 | Study 1
The primary endpoint of Study 1 was the correlation of the AMH 
concentration with the oocyte count. A regression analysis was per-
formed in order to determine if AMH was significantly and strongly 
associated with the oocyte count (response variable: oocyte count; 
explanatory variables: age, AMH, LH, FSH, E2, and P4).
The Guideline of the European Society of Human Reproduction 
and Embryology18 was used and the patients were grouped as 
“poor” responders (P- arm: less than three oocytes), “normal” re-
sponders (N- arm: 4- 14 oocytes), and “high” responders (H- arm: >15 
oocytes). The receiver operating characteristic (ROC) curves were 
plotted in order to assess the P- arm and N- arm, N- arm, and H- arm 
by AMH, FSH, and E2. The area under the curve (AUC) also was 
compared for each parameter to determine whether AMH was su-
perior to the other parameters regarding the predictive ability of the 
oocyte count.
The secondary endpoints were as follows: an assessment of the 
correlation of the AMH, FSH, and E2 concentrations with the oocyte 
count and an assessment of whether the correlation with AMH was 
the strongest among the studied markers.
2.4.2 | Study 2
The primary endpoint of Study 2 was to investigate the distribution of 
the AMH concentration for each age group in order to create a cor-
relation chart of age and AMH concentration.
2.5 | Ethics and study oversight
This study was carried out according to the Declaration of Helsinki, 
as well as the Japanese laws and regulatory requirements. All the 
participants, or their legally acceptable representatives, provided 
written informed consent prior to entering the study. The protocol, 
F I G U R E  1 Patient disposition (per- analysis sets)
TABLE  1 Demographic and clinical characteristics of the 
participants in Study 1 (n = 236)
Variable Median Interquartile range
Age (years) 36 33- 39
Height (cm) 160.0 156.0- 162.4
Weight (kg) 51.2 48.0- 55.0
Body mass index (kg/m2) 20.1 19.1- 21.8
Mature oocytes (N) 13 7- 19
MII oocytes (N) 11 7- 19
Retrieved oocytes (N) 14 9- 23
Elecsys AMH (ng/mL) 2.38 1.47- 3.75
LH (mIU/mL) 4.80 3.71- 6.09
FSH (mIU/mL) 7.08 6.11- 8.75
E2 (pg/mL) 40.7 30.4- 54.4
P4 (ng/mL) 0.384 0.260- 0.502
AMH, anti- Müllerian hormone; E2, estradiol; FSH, follicle- stimulating hor-
mone; LH, luteinizing hormone; MII, metaphase II; P4, progesterone.
TABLE  2 Demographic and clinical characteristics of the 
participants in Study 2 (n = 417)
Variable Median Interquartile range
Age (years) 36 30- 41
Height (cm) 158.5 154.8- 162.0
Weight (kg) 52.6 48.9- 56.0
Body mass index (kg/m2) 20.7 19.5- 22.3
AMH (ng/mL) 2.42 1.15- 4.77
LH (mIU/mL) 5.84 3.83- 8.50
FSH (mIU/mL) 6.04 4.38- 7.71
E2 (pg/mL) 80.5 49.2- 153.6
P4 (ng/mL) 0.483 0.307- 3.890
AMH, anti- Müllerian hormone; E2, estradiol; FSH, follicle- stimulating hor-
mone; LH, luteinizing hormone; P4, progesterone.
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F IGURE  2 Relationships between 
(A) anti- Müllerian hormone (AMH), (B) 
follicle- stimulating hormone (FSH), and (C) 
estradiol (E2) by the number of retrieved 
oocytes
F IGURE  3 Box and whisker plot for 
(A) anti- Müllerian hormone (AMH), (B) 
follicle- stimulating hormone (FSH), and (C) 
estradiol (E2) in patients within each group 
divided by the number of oocytes retrieved. 
Poor ≤3 (n = 5); normal = 4- 14 (n = 123); 
high ≥15 (n = 108). The P- values refer to 
the t tests of the means of each group
(A) (B)
(C)
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amendments, and informed consent form were approved by the in-
stitutional review board or independent ethics committee at each site 
prior to the study’s commencement.
2.6 | Statistical methods
All the statistical analyses were performed by using IBM SPSS 
Statistics for Windows (v. 19; IBM Corporation, Armonk, NY, USA) 
and SAS (v. 9.2; SAS Institute, Cary, NC, USA). The distribution of the 
response variables and explanatory variables was confirmed by non- 
parametric tests (one- sample Kolmogorov- Smirnov test) and the data 
normalization was performed by power transformation. The explana-
tory variables were selected after confirming the possible factors of 
multicollinearity from the correlation matrix. A regression analysis 
was performed by using these explanatory variables and a stepwise 
model was used to establish correlations with the response variables. 
The AUC values of the plotted ROC curves (significance test [null hy-
pothesis: AUC = 0.5]) were compared. Also calculated and compared 
were the correlation coefficients. All the tests were two- sided, with 
an alpha level of 5%.
3  | RESULTS
3.1 | Demographic and clinical characteristics of the 
participants
In Study 1, 335 participants were enrolled, 330 were included in the 
full analysis set, and 236 participants who were undergoing COS 
were included in the per- protocol set (an oocyte count was per-
formed) (Figure 1). Five participants were excluded because they 
met the exclusion criteria, while 93 participants discontinued for 
the following reasons: their oocyte retrieval failed, pregnancy was 
achieved by other methods, the patient’s decision, or the oocyte 
collection used clomiphene. One participant was excluded as she 
was diagnosed with hyperthyroidism, based on her TSH and FT4 
levels. Finally, 236 participants who were undergoing COS were 
analyzed in Study 1 and 417 healthy participants were analyzed in 
Study 2.
The participants in Study 1 had a median (range) age of 36 (33- 
39) years, a median (range) BMI of 20.1 (19.1- 21.8) kg/m2, median 
F IGURE  4 Receiver operating characteristic curve analysis 
showing the predictive value of anti- Müllerian hormone (AMH) 
for the estimation of high responders (≥15 oocytes retrieved). A, 
Prediction of a normal and a high response. The area under the 
curve (AUC) of the receiver operating characteristic curve for the 
N- arm, compared to the H- arm, was 0.818 (95% confidence interval, 
CI: .763- .872, P < .001) for AMH, 0.632 (95% CI: 0.560- 0.703, 
P = .001) for follicle- stimulating hormone (FSH), and .512 (95% CI: 
0.437- 0.587, P = .757) for estradiol (E2). B, Prediction of a poor and 
a normal response. The AUC of the receiver operating characteristic 
curve for the P- arm, compared to the N- arm, was .717 (95% CI: 
0.607- 0.827, P = .101) for AMH, .613 (95% CI: 0.338- 0.888, P = .338) 
for FSH, and 0.558 (95% CI: 0.349- 0.767, P = .662) for E2
F IGURE  5 Relationship between anti- Müllerian hormone (AMH) 
and the number of retrieved oocytes
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(range) AMH concentration of 2.38 (1.47- 3.75) ng/mL, and median 
number of retrieved oocytes was 14 (9- 23) (Table 1). The participants 
in Study 2 had a median (range) age of 36 (30- 41) years, median 
(range) BMI of 20.7 (19.5- 22.3) kg/m2, and median AMH concentra-
tion of 2.42 (1.15- 4.77) ng/mL (Table 2).
3.2 | Correlation of anti- Müllerian hormone, 
follicle- stimulating hormone, and estradiol with the 
oocyte count
Based on the correlation coefficient (r = .600), there was an intermedi-
ate positive correlation between the AMH level and the oocyte count 
(Figure 2). There was a weak negative correlation (r = −.283) between 
the FSH level and the oocyte count. There was no correlation be-
tween the E2 level and the oocyte count (P = .498).
3.3 | Predictive ability of the ovarian response by 
anti- Müllerian hormone
Regarding the ovarian response, the predictive ability of AMH was 
statistically significant (P < .001), except between the P+N- arms 
(Figure 3). The predictive ability of FSH was only significant (P < .001) 
between the N+H- arms. The predictive ability of E2 did not reach 
statistical significance, which was determined by calculating the 
Variable N
All items
After conducting the stepwise 
model
Standardized partial 
regression 
coefficient P- value
Standardized partial 
regression 
coefficient P- value
AMH 236 .569 <.001 .587 <.001
Age 236 −.129 .018 −.129 .017
LH 236 −.047 .392 – –
FSH 236 −.076 .197 – –
E2 236 −.018 .723 – –
P4 236 −.014 .784 – –
AMH, anti- Müllerian hormone; E2, estradiol; FSH, follicle- stimulating hormone; LH, luteinizing hor-
mone; P4, progesterone.
TABLE  3 Summary of the regression 
analysis results
F IGURE  6 Age- specific anti- Müllerian hormone (AMH) concentrations. (●) Mean ± standard deviation; (△) median
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asymptote P- value of the AUC in case the null hypothesis was .5 (sig-
nificance level of .05).
Regarding the predictive ability of AMH of the ovarian response, 
based on a ROC curve analysis and comparison of the AUC values of 
each arm (Figure 4), AMH had a significantly (P<.001) higher predictive 
value for the normal and high responders, compared with FSH and E2, 
and a lower predictive value for the poor and normal responders, com-
pared with FSH and E2. The FSH seemed to have a lower predictive 
value, compared with AMH, but a higher predictive value, compared 
with E2.
The AUC of AMH was .818 (95% CI: 0.763- 0.872), with the high-
est precision in the N+H- arms. The AUC of AMH was clearly higher, 
compared with the other two parameters. The AMH yielded the high-
est ovarian response predictive ability. As the P- arm only included five 
patients, the AUC did not reach statistical significance; thus, the N+P- 
arm assessment was not sufficiently reliable.
Then, the H- arm (high risk of OHSS) was analyzed separately 
from the other arms (P- and N- arms). However, no significant differ-
ence was found when analyzing the N- arm, compared to the H- arm, 
and the P+N- arms, compared to the H- arm. The AUC of AMH was 
.824 (95% CI: 0.771- 0.877, P < .001), indicating that AMH had a high 
predictive value of the ovarian response and OHSS, compared to FSH 
and E2.
3.4 | Regression analysis: Correlation of anti- 
Müllerian hormone with the oocyte count
A regression analysis was performed in order to evaluate the correla-
tion of AMH with the oocyte count (response variable: oocyte count; 
explanatory variables: age, AMH, LH, FSH, E2, and P4 [primary end-
point]). The standardized partial regression coefficient of AMH was 
.569 (Table 3). A strong correlation between the AMH concentration 
and the ovarian response was found (Figure 5).
3.5 | Distribution of the anti- Müllerian hormone 
concentration
The age- specific distribution of AMH concentrations is shown in 
Figure 6. The single- year- specific median, mean, and standard devia-
tion values are summarized in Table 4. Both the mean and median 
AMH concentrations decreased progressively with age. Five patients 
had an undetectable AMH concentration (<.01 ng/mL) and were aged 
≥44 years. Figure 7 shows the median levels, 95% range (2.5- 97.5th 
percentile value), and 25- 75th percentile values of each age group. 
The AMH concentration decreased progressively by age group, with 
the highest median concentration (5.96 ng/mL) found among the 
women who were aged 20- 24 years and the lowest median concen-
tration (0.32 ng/mL) among the women who were aged 45- 49 years 
(Table 5).
4  | DISCUSSION
This multicenter, observational, multipart study showed that AMH 
had the strongest and highly significant correlation with the oocyte 
count, compared with FSH and E2, especially among those patients 
who were classified as normal and high responders to COS for IVF. 
Among the patients who were undergoing COS, AMH yielded the 
highest ovarian response predictive ability.
Although several clinical trials have been conducted in the USA,19 
there is little information regarding potential ethnic differences 
in the serum AMH concentrations.20-23 Additionally, the distribu-
tion of AMH concentrations has been reported previously, but the 
data were mainly obtained from patients with infertility, rather than 
from healthy controls.24 As the distribution of AMH levels in healthy 
Japanese women had yet to be reported, this study aimed to address 
this particular knowledge gap in Japan. Data on the potentially useful 
F IGURE  7 Anti- Müllerian hormone 
(AMH) concentration by age group. The 
values are the medians (lines), 25- 75th 
percentiles (boxes), and 95% range 
(2.5- 97.5th percentiles) (whiskers)
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predictors of the ovarian response have gained particular importance 
as the need for infertility treatment has been increasing in Japan. 
As far as the authors know, this study is the first to determine the 
age- specific distribution of the serum AMH concentration in healthy 
Japanese women with a normal menstrual cycle. As shown in other 
studies, the AMH concentration in Japanese women decreased pro-
gressively by age group. The results obtained in Study 2 will serve as 
preliminary data for the use of AMH in clinical practice in Japan as 
it was possible to evaluate the age- specific distribution of the AMH 
concentration in a relatively large population (417 Japanese partici-
pants) of women who were aged between 20 and 49 years with nor-
mal menstrual cycles.
The currently available clinical data regarding AMH are growing 
as AMH is being recognized as a useful marker and predictor of the 
ovarian response.5,6,9,10,13-15 As infertility treatments become more 
readily available to couples with infertility and reproductive issues 
worldwide, the accurate and safe assessment and prediction of the 
ovarian response have gained considerable importance. It is of par-
ticular importance to predict the risk of OHSS of patients who are 
considered as potentially high responders to COS because they are 
at higher risk of developing OHSS, which could be a severe and life- 
threatening condition. In the present study, AMH had a significantly 
(P < .001) higher predictive value for normal responders, compared 
to high responders, and poor + normal responders, compared to high 
responders, compared with the other evaluated parameters. In order 
to discriminate the high responders (high risk of OHSS) from the 
other arms (poor + normal), the other arms were analyzed separately. 
However, no significant difference was found when analyzing the 
normal responders, compared to the high responders, and the poor 
+ normal responders, compared to the high responders. The reason 
for the lack of significant difference between the poor + normal re-
sponders and the high responders was the small number of patients in 
the P- arm. The P- arm consisted of only five patients, while the N- arm 
consisted of 123 patients. Furthermore, regarding the median AMH 
concentrations, those in the P- arm and N- arm were 1.20 and 1.74 ng/
mL, respectively, compared with those in the H- arm (3.58 ng/mL). 
Finally, the AMH concentration varied widely among individuals. Up 
to 20% of the patients in the N- arm had a relatively low AMH concen-
tration. Given the lower concentrations and few participants, the P+N- 
arms had little influence on the results; thus, there was not enough 
power to detect large differences.
One report indicated that the method of measuring the AMH con-
centration has not been standardized. Additionally, the need for assay- 
specific interpretation was emphasized as AMH concentrations can be 
remarkably different, depending on the assay system that is used for 
quantification.25 Additionally, limitations across countries regarding 
the availability of equipment should be considered when standardiz-
ing such parameters. For instance, Gen II ELISA is not readily available 
in Japan;24 thus, it is necessary to obtain data with other systems that 
are locally available.
TABLE  4 Age- specific median, mean, and 1- specificity (1SD) for 
the serum anti- Müllerian hormone levels (ng/mL) of 417 healthy 
Japanese women who were enrolled at three centers between May, 
2014 and May, 2015
Age (years) N Median Mean 1SD
20 4 6.2 6.9 3.9
21 3 2.9 4.7 4.4
22 13 7.4 7.1 2.4
23 15 6.5 7.0 3.8
24 11 4.2 4.3 1.5
25 9 5.8 6.2 2.6
26 11 4.5 5.0 2.5
27 9 5.3 5.6 3.2
28 13 5.5 5.2 2.2
29 15 5.4 5.5 1.8
30 12 2.6 3.9 2.3
31 17 5.0 5.4 2.2
32 25 2.6 4.3 4.0
33 16 2.7 3.5 2.2
34 16 3.3 4.0 3.2
35 17 2.7 3.2 2.0
36 20 2.0 2.8 2.0
37 16 1.8 2.2 1.2
38 17 2.2 2.0 1.1
39 21 2.0 2.4 1.7
40 27 1.6 2.3 2.2
41 13 1.3 1.6 1.1
42 22 1.2 1.2 .7
43 19 1.4 1.4 1.0
44 14 .9 1.7 1.8
45 8 .2 .4 .4
46 12 .4 .5 .5
47 7 .4 .4 .4
48 10 .2 .4 .5
49 5 .6 .6 .4
TABLE  5 Age- specific median and interquartile range for the 
serum anti- Müllerian hormone levels (ng/mL) of 417 healthy 
Japanese women who were enrolled at three centers between May, 
2014 and May, 2015 at a 3 year interval for those aged 30- 44 years 
and a 5 year interval for those aged 20- 29 years and >45 years
Age (years) N Median Interquartile range
20- 24 46 5.96 3.30- 7.87
25- 29 57 5.27 3.49- 6.88
30- 32 54 4.00 2.06- 6.18
33- 35 49 2.91 1.87- 4.76
36- 38 53 1.96 1.29- 3.07
39- 41 61 1.72 1.07- 2.92
42- 44 55 1.13 0.51- 1.86
45- 49 42 .32 0.15- 0.74
Total 417 2.42 1.15- 4.77
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Many studies have assessed the prediction of the ovarian re-
sponse by the AMH concentration, but most of them quantified 
AMH by ELISA, which has been reported as a method that lacks 
precision.5 In Study 1, the predictive ability of the ovarian response 
was assessed by an automatic immunoanalyzer system that uses 
electrochemiluminescence. According to the present analyses 
of the tested parameters, AMH showed the highest correlation 
(r = .66, intermediate positive correlation) with the ovarian re-
sponse, while FSH and E2 were only weakly correlated (r = −.283, 
r = .044).
This study has several limitations. Regarding the assessment of 
the predictive ability of the ovarian response by AMH, the P- arm only 
included five patients, which precluded the researchers from finding 
significant differences; thus, the N+P- arm assessment was not suffi-
ciently reliable. Although a lack of generalizability could be a limita-
tion of this study, as patients from two centers only were included, 
the age- specific distribution of the AMH concentration was evaluated 
in a relatively large population (417 Japanese participants) of women 
who were aged between 20 and 49 years with normal menstrual cy-
cles. The authors consider that because these AMH concentration 
data were collected from a relatively large number of women with such 
characteristics, these data will serve as a point of reference for future 
studies in Japan.
In conclusion, the mean serum AMH concentration decreased pro-
gressively with age. Additionally, the AMH concentration correlated 
well with the oocyte count in those patients who were undergoing 
COS for IVF. This study’s results support the widespread use of AMH 
as a marker of the ovarian reserve and ovarian response, which also 
was shown to predict the risk of OHSS among the patients who were 
undergoing COS. Thus, quantifying the AMH concentration prior to 
selecting an individualized COS protocol will be useful for ensuring 
patients’ safety and improved outcomes, not only in assisted repro-
ductive techniques but also in fertility preservation after cancer 
treatment.26,27
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